The preclinical studies of the stress-protective activity of “Tonus-aktiv” homeopathic granules
DOI:
https://doi.org/10.24959/nphj.20.36Keywords:
homeopathy, chronic fatigue syndrome, preclinical studies, stress-protective activityAbstract
Aim. To perform the preclinical studies of the stress-protective activity of a new “Tonus-Aktiv” homeopathic medicinal product.
Materials and methods. The stress-protective effect of the “Tonus-Aktiv” homeopathic medicinal product (MP) and the reference drug – “Stress-gran” homeopathic granules were studied on the model of neuromuscular tension by Selye. The stress-protective effect of the drugs was assessed by the conventional methods described in the scientific literature and the corresponding current instructional guidelines. All factual material was processed by variational statistics methods using parametric (Newman-Keuls test) and non-parametric methods of analysis (Kruskal-Wallis, Mann-Whitney).
Results and discussion. It was found that “Tonus-Aktiv” had a pronounced gastro-protective effect, reducing the area of ulcers by almost 3 times, having a statistically significant antioxidant effect, reducing the level of TBA (thiobarbituric acid) active products in the liver homogenate. It did not have a normalizing effect on the protein metabolism, but it did contribute to enhancing energy-supplying metabolic processes: aerobic glycolysis indicated by a reliable increase of the pyruvic acid level in the blood serum, and lipolysis, as evidenced by a significantly higher level of the total blood lipids. “Tonus-Aktiv” showed a pronounced antioxidant activity: it reduced the TBA level of active products in the liver homogenate. At the same time, the level of endogenous antioxidant of reduced glutathione was observed to be lower than in the stressed animals against the background of the “Tonus-Aktiv” application. It indicates the physiological nature of the stress protective activity of the drug.
Conclusions. A moderate stress-protective activity of “Tonus-Aktiv” homeopathic granules can be observed; it is caused by antioxidant properties, as well as a probable activating effect on the hypothalamic-pituitary-adrenal system, which may be manifested by the protective action.
References
Hurskaia, O. H. (2012). Narusheniia immunnoho statusa u bolnykh sindromom khronicheskoi ustalosti, assotsiirovannym s herpesvirusnoi infektsiei. Extended abstract of candidates thesis. Moscow, 23.
Chronic Fatigue Syndrome Centers for Disease Control and Prevention. Available at: http: //www.cdc.gov/cfs/general/index.html.
Hatziagelaki, E., Adamaki, M., Tsilioni, I., Dimitriadis, G., Theoharides, T. C. (2018). Myalgic encephalomyelitis/chronic fatigue syndrome-metabolic disease or disturbed homeostasis due to focal inflammation in the hypothalamus? J Pharmacol Exp Ther, 367,155–167.
Wilshire, C. E., Kindlon, T., Courtney, R., Matthees, A., Tuller, D., Geraghty, K. (2018). Rethinking the treatment of chronic fatigue syndrome – a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. BMCPsychol., 6, 6.
Boiko, T. I. (2010). Klinichni laboratorni doslidzhennia. Kyiv: Medytsyna, 352.
Castro-Marrero, J., Sáez-Francàs, N., Santillo, D., Alegre, J. (2017). Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome. Br J Pharmacol., 174, 345-369.
Nahorna, O., Bukhtiarova, T., Talaieva, T. et al. (2014). Nastanova ST-N MOZU 42-6.0:2014. «Doklinichni doslidzhennia bezpeky yak osnova klinichnykh vyprobuvan za uchastiu liudyny i reiestratsii likarskykh zasobiv (ICH M3 (R2))». Kyiv: MOZ Ukrainy, 47.
Mishchenko, O. Ya. (2010). Klinichna farmatsiia, 14 (1), 42-48.
Kraidashenko, O. V., Kupnovytska, I. H., Klishch, I. M., Lyzohub, V. H. (Eds.). (2010). Farmakoterapiia. Vinnytsia: Nova Knyha, 644.
Ocheretna, O. L. (2014). Biomedical and biosocial anthropology, 23, 281-284.
Liubovych, O. Ye., Klishch, I. M. (2018). Visnyk naukovykh doslidzhen, 4, 175-179.
Lutsenko R. V., Sydorenko, A. H., Bobyrov, V. M. (2013). Problemy ekolohii i medytsyny, 17 (1-2), 71-74.
Council of Europe. (1986). Europen convention for the protection of vertebrate animals used for experimental and other scientific purposes. Strasburg, 123, 52.
Osnovnye metody statisticheskoi obrabotki rezultatov farmakolohicheskikh eksperimentov. Rukovodstvo po eksperimentalnomu (doklinicheskomu) izucheniiu novykh farmakolohicheskikh veshchestv. (2000). Moscow: Remedium, 349-354.
Chaban, O. S., Frankova, I. A. (2015). NEYRONEWS, 2 (66), 8-18.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
